MARKET

KALA

KALA

Kala Pharmaceuticals Inc
NASDAQ
0.1630
-0.0101
-5.83%
After Hours: 0.1661 +0.0031 +1.90% 19:07 04/01 EDT
OPEN
0.1800
PREV CLOSE
0.1731
HIGH
0.1980
LOW
0.1615
VOLUME
5.71M
TURNOVER
--
52 WEEK HIGH
20.60
52 WEEK LOW
0.1607
MARKET CAP
148.55M
P/E (TTM)
-0.0275
1D
5D
1M
3M
1Y
5Y
1D
Kala Bio Engages Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
Barchart · 17h ago
Kala Bio Delays 2025 Annual Report Filing
TipRanks · 20h ago
Kala Bio delays filing annual report, cites management turnover and strategic shift
Reuters · 1d ago
Kala Bio Highlights Launch Of Agentic AI Platform
Benzinga · 2d ago
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch
Benzinga · 2d ago
Weekly Report: what happened at KALA last week (0323-0327)?
Weekly Report · 2d ago
KALA BIO Delivers Industry-Leading AI Infrastructure: Bionic Intelligence Research Agent Now Live
Barchart · 2d ago
Weekly Report: what happened at KALA last week (0316-0320)?
Weekly Report · 03/23 10:08
More
About KALA
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Webull offers KALA BIO Inc stock information, including NASDAQ: KALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KALA stock methods without spending real money on the virtual paper trading platform.